284 related articles for article (PubMed ID: 35008186)
1. Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
Brancati S; Gozzo L; Romano GL; Vetro C; Dulcamare I; Maugeri C; Parisi M; Longo L; Vitale DC; Di Raimondo F; Drago F
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008186
[TBL] [Abstract][Full Text] [Related]
2. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.
Piccini M; Mannelli F; Coltro G
Bioengineering (Basel); 2023 May; 10(5):. PubMed ID: 37237661
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
4. Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.
Chen X; Zhao Y; Li Q; Fan S
Onco Targets Ther; 2023; 16():409-419. PubMed ID: 37334144
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting.
Gong X; He X; Wang L; Yu T; Liu W; Xu H; Jin L; Li X; Zhang B; Tao Z; Qian W
Exp Hematol Oncol; 2024 Feb; 13(1):17. PubMed ID: 38365742
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparison of salvage intensive chemotherapy
Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.
Piccini M; Pilerci S; Merlini M; Grieco P; Scappini B; Bencini S; Peruzzi B; Caporale R; Signori L; Pancani F; Vannucchi AM; Gianfaldoni G
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33919958
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
Rahmé R; Braun T
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256681
[No Abstract] [Full Text] [Related]
11. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center.
Freeman T; Williams K; Puto M; Waller A; McLaughlin EM; Blachly JS; Roddy J
World J Oncol; 2023 Feb; 14(1):40-50. PubMed ID: 36896000
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.
Chatzikalil E; Roka K; Diamantopoulos PT; Rigatou E; Avgerinou G; Kattamis A; Solomou EE
J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610812
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S; Hospital MA; Alary AS; Saillard C; Hicheri Y; Mohty B; Rey J; D'Incan E; Charbonnier A; Villetard F; Maisano V; Lombardi L; Ittel A; Mozziconacci MJ; Gelsi-Boyer V; Vey N
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454930
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions.
Samra B; Konopleva M; Isidori A; Daver N; DiNardo C
Front Oncol; 2020; 10():562558. PubMed ID: 33251134
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
19. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting.
Gong X; Zhang Y; He X; Moloudizargari M; Yu T; Wang L; Liu W; Jin L; Xu H; Xu Y; Tao Z; Qian W
Exp Hematol Oncol; 2023 Jun; 12(1):57. PubMed ID: 37391809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
